Q-omics provides the consensus-scored RAB17 profile across patient tissues and cancer cell-line models. RAB17 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RAB17 is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, RAB17 protein abundance shows 28,682 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, THCA, and LUAD as cancer lineages where RAB17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAB17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAB17 survival associations across molecular data types. RAB17 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAB17 RNA expression–survival associations across cancer types. High RAB17 expression shows unfavorable associations in LGG, HNSC and LAML, but favorable associations in KIRC, KIRP and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RAB17 RNA expression.
This table summarizes RAB17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 9. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RAB17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAB17 shows lower tumor expression in THCA, KIRP, LUAD, KIRC and LUSC and higher tumor expression in BRCA. The THCA box plot shows higher RAB17 RNA expression in normal versus tumor tissue (log2 FC = −1.060, t-test p < 0.001).
This table shows molecular features associated with RAB17 in patient tissues and cancer cell lines. In patient samples, RAB17 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, RAB17 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BREAST.
